LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Ovid therapeutics Inc

Chiusa

SettoreSettore sanitario

0.31 -3.12

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.3

Massimo

0.34

Metriche Chiave

By Trading Economics

Entrata

-982K

-10M

Vendite

54K

130K

EPS

-0.14

Margine di Profitto

-7,873.077

Dipendenti

23

EBITDA

-1.8M

-12M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+732.35% upside

Dividendi

By Dow Jones

Utili prossimi

12 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-4.3M

21M

Apertura precedente

3.43

Chiusura precedente

0.31

Notizie sul Sentiment di mercato

By Acuity

50%

50%

162 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 giu 2025, 20:51 UTC

Utili

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 giu 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 giu 2025, 20:48 UTC

Discorsi di Mercato

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 giu 2025, 20:46 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

27 giu 2025, 20:46 UTC

Discorsi di Mercato

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 giu 2025, 19:31 UTC

Discorsi di Mercato

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 giu 2025, 19:19 UTC

Discorsi di Mercato

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 giu 2025, 19:16 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 giu 2025, 18:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 giu 2025, 18:42 UTC

Discorsi di Mercato

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 giu 2025, 18:39 UTC

Discorsi di Mercato
Utili

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 giu 2025, 18:29 UTC

Discorsi di Mercato

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 giu 2025, 18:18 UTC

Discorsi di Mercato

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 giu 2025, 18:16 UTC

Discorsi di Mercato

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 giu 2025, 17:16 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 giu 2025, 17:08 UTC

Utili

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 giu 2025, 16:52 UTC

Acquisizioni, Fusioni, Takeovers

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 giu 2025, 16:22 UTC

Utili

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

27 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

27 giu 2025, 15:59 UTC

Discorsi di Mercato

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 giu 2025, 15:56 UTC

Discorsi di Mercato

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Confronto tra pari

Modifica del prezzo

Ovid therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

732.35% in crescita

Previsioni per 12 mesi

Media 2.83 USD  732.35%

Alto 4 USD

Basso 1.5 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ovid therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.275 / 0.33Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

162 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.